Generate Biomedicines (NASDAQ:GENB) Trading Up 8.1% – Should You Buy?

Generate Biomedicines Inc (NASDAQ:GENB) shares were up 8.1% during mid-day trading on Monday . The company traded as high as $14.12 and last traded at $14.2090. Approximately 77,430 shares traded hands during trading, a decline of 84% from the average daily volume of 476,821 shares. The stock had previously closed at $13.15.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. HC Wainwright began coverage on Generate Biomedicines in a report on Monday, April 13th. They set a “buy” rating and a $16.00 target price for the company. The Goldman Sachs Group started coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 price target on the stock. Wall Street Zen raised shares of Generate Biomedicines to a “hold” rating in a research note on Saturday, March 14th. Cantor Fitzgerald initiated coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating on the stock. Finally, Zacks Research upgraded shares of Generate Biomedicines to a “hold” rating in a research note on Wednesday, March 25th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.20.

Generate Biomedicines Stock Up 10.0%

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.